DnB Asset Management AS Grows Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

DnB Asset Management AS increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.3% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 26,733 shares of the biopharmaceutical company’s stock after acquiring an additional 1,335 shares during the period. DnB Asset Management AS’s holdings in Alnylam Pharmaceuticals were worth $6,291,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ALNY. Quantbot Technologies LP raised its stake in shares of Alnylam Pharmaceuticals by 1,754.5% in the 3rd quarter. Quantbot Technologies LP now owns 204 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 193 shares during the period. Bridgewater Associates LP purchased a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $551,000. Captrust Financial Advisors lifted its stake in Alnylam Pharmaceuticals by 34.4% during the third quarter. Captrust Financial Advisors now owns 4,833 shares of the biopharmaceutical company’s stock worth $1,329,000 after purchasing an additional 1,237 shares in the last quarter. True Wealth Design LLC boosted its position in shares of Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 153 shares during the period. Finally, Erste Asset Management GmbH acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at $4,539,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Buying and Selling

In other news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the sale, the executive vice president now owns 12,881 shares in the company, valued at approximately $3,240,344.36. This trade represents a 10.06 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Yvonne Greenstreet sold 1,213 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the transaction, the chief executive officer now owns 81,526 shares in the company, valued at approximately $20,802,989.42. This trade represents a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock valued at $19,958,097 over the last quarter. 1.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

ALNY has been the subject of a number of research analyst reports. Wells Fargo & Company raised their target price on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an “equal weight” rating in a report on Friday, March 21st. Scotiabank lifted their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the company a “sector outperform” rating in a report on Friday, March 21st. Citigroup increased their target price on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a “buy” rating in a report on Friday, March 21st. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 21st. Finally, William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $312.30.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $268.46 on Monday. The stock has a market cap of $34.92 billion, a P/E ratio of -123.71 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The stock has a 50 day moving average of $259.86 and a two-hundred day moving average of $260.52. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.